Infections of the Immunocompromised Host
Pathogens that are harmless to healthy individuals can become life-threatening for immunocompromised patients. Scientists search for new ways of protection.
Surgery, tumour treatment and intensive care medicine improve life expectancies of many patients. However, these measures and therapies come at a price: they weaken the immune system and increase susceptibility even to “harmless” pathogens. Infections in patients with compromised immune systems are playing an ever increasing role in the day-to-day life of hospitals and are often difficult to treat with conventional antibiotics.
It is currently almost impossible to estimate the precise factors which weaken a specific patient’s immune system. DZIF scientists in the research field “Infections of the Immunocompromised Host” research appropriate biomarkers for estimating such risks and develop vaccines and immunotherapies to strengthen the immune system and protect immunocompromised patients from infection.
Central Themes
-
Biomarkers for infection control and risk estimation
-
Scientists aim to find biomarkers that indicate infection risks and demonstrate potential options for specifically strengthening the immune system.
-
Developing new antiviral therapies
-
Vaccines and targeted immune modulation
-
Preventive and therapeutic vaccines present attractive options for preventing infection in immunocompromised patients. DZIF scientists develop new vaccine candidates.
-
Developing adoptive immunotherapies
-
An attractive alternative to vaccines is to strengthen the immune system by transferring specific immune system cells, particularly memory T cells which have already undergone clinical trials in Munich.